VIDEO: Pediapharm (CVE:PDP) CEO talks major sales increase to the tune of 64%
President & CEO of Pediapharm (CVE: PDP, OTCMKTS: PDDPF) Sylvain Chretien talks to James about how they were able to achieve a 64% sales increase as well as achieve their first ever positive EBITA. Pediapharm’s major focus is on pharmaceuticals for children and young adults.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.